Introduction
The availability of potent selective antagonists of GnRH has provided new opportunities to investi¬ gate the role of pituitary LH in the control of corpus luteum function in primates. So far, however, the use of this approach has produced conflicting results. In an early study, Balmaceda et al (1983) reported normal luteal function in rhesus monkeys after daily injections of GnRH antagonist throughout the luteal phase, thus suggesting that luteal function is independent of continued luteotrophic support. In contrast, convincing evidence that luteal function does depend upon pituitary LH secretion has been obtained by Fraser et al. (1985 Fraser et al. ( , 1986 who demonstrated that a single injection of GnRH antagonist during the mid-late luteal phase in stumptailed monkeys results in inhibition of progesterone secretion and premature luteal regression. This discrepancy in findings is unlikely to be due to species differences since other experimental approaches resulting in pituitary gonadotrophin deprivation in rhesus monkeys support the view that luteal function requires pituitary luteotrophic support (Hutchison & Zeleznik, 1984 . A more likely explanation is that the results of Balmaceda et al (1983) were due to incomplete suppression of LH release by an antagonist of lesser potency than that used in the later studies.
The use of GnRH antagonists to investigate the gonadotrophic requirements for corpus luteum function in other non-human primates has not been reported. In the present study we have examined the effects of a single subcutaneous injection of a novel highly potent GnRH antagonist on pituitary LH secretion and luteal function in the marmoset monkey, Callithrixjacchus. Since there is evidence in primates that luteal sensitivity to gonadotrophin deprivation changes with the age of the corpus luteum (Fraser et al, 1985) , the effects of acute withdrawal of LH were investigated during the early and mid-luteal phase. Luteal function was assessed by the measurement of circulating progesterone concentrations. The development of a sensitive microtitre plate enzyme immunoassay for the direct measurement of marmoset plasma progesterone is also described.
Materials and Methods
Animals. Adult female marmoset monkeys weighing 350^400 g and having regular ovarian cycles were used. The animals were paired with castrated (N = 2) or vasectomized (N = 6) males and housed in the Institute of Zoology primate colony under conditions previously described (Harlow et al., 1983; . Blood samples (0-2 ml) were collected from the femoral vein of unsedated animals into 1 0 ml heparinized syringes and placed immediately on ice. The blood was centrifuged at 500 g for 20 min and the plasma was stored in two aliquots at -20°C until assayed. Ovarian cycles were monitored throughout the study by the measurement of plasma progesterone concentrations. The day of ovulation was defined as that preceding the day on which progesterone concentrations rose above a value of 10 ng/ml and the last day of the luteal phase as the day preceding the fall of progesterone concentrations below 10 ng/ml (Harlow et al., 1983) . Marmosets in our colony have a mean + s.e.m. cycle length of 28-6 ± 1 -0 days with a luteal phase of 19-2 ± 0-6 days (Harlow et al., 1983) .
Experimental protocol. Each animal was studied for one control cycle before receiving the GnRH antagonist (cloprostenol-injected) cycles were compared using a paired / test. Since samples were collected every other day, data for each animal were plotted separately and the line connecting two adjacent sample points was used to estimate the day on which progesterone concentrations first exceeded a value of 10 ng/ml. Results obtained in this way agree well with those obtained from progesterone measurements in daily samples (Harlow et al., 1983; J. . Hodges, unpublished observations) .
Progesterone enzyme immunoassay. Plasma progesterone was measured in unextracted samples using a modification ofthe heterologous enzyme immunoassay procedure described by Sauer et al. ( 1986) . The antiserum was raised in a sheep after immunization against progesterone-11 -hemisuccinate conjugated to ovalbumin. The gamma-globulin fraction The anti-progesterone gamma-globulin was diluted 1:2000 in O-lSmM-sodium acetate buffer, pH 50 and 200 µ were added to each well of microtitre plates which were then covered and left for 3 h at room temperature in a covered plastic box lined with damp paper (humid chamber). The plates were emptied by inversion, PAS-gelatin buffer (300 µ ) was added to each well and the plates were tightly sealed with plastic film before storing at 4°C.
Assay procedure. Microtitre plates coated with antibody were emptied, rinsed with PAS-gelatin buffer and blotted dry immediately before use. For each assay, 10 µ of progesterone in toluene (1 µg/ml) were dried down under nitrogen and reconstituted in 1 ml standard diluent (PAS-gelatin buffer containing charcoal-treated marmoset plasma at 1:15, v/v). A 200 µ sample of this solution was double diluted over the range 10 000-156 pg/ml (equivalent to 200-1-5 pg/ well after further dilution with a solution of conjugate). Unextracted plasma samples (5 µ ) and quality controls were diluted 1:30 with sample diluent (PAS-gelatin buffer containing charcoal-treated marmoset plasma at 1:30, v/v). Volumes of 100 µ of diluted sample, quality control and standard were transferred to clean tubes to which 400 µ of conjugate (1:1000) Fig. 1 . Under the assay conditions described, absorbance (optical density) readings at 405 nm were normally within the range 1-1-1-3 (Opg progesterone) to 0-1-0-15 (200 pg progesterone). The sensitivity of the assay, defined as the amount of progesterone resulting in 90% binding compared to E0, was 1-5-2-0 pg/well. At the high dilutions of marmoset plasma used, this gave a value for the limit of detection of the assay of 1-1-1-5 ng progesterone/ml. Serial dilutions of marmoset plasma containing concentrations of progesterone typical of those found during the luteal and follicular phases of the cycle gave displacement curves parallel to that obtained with progesterone standards (Fig. 1) . There was no significant displacement of binding with charcoal-treated marmoset plasma. Crossreactivities of the antiserum with other steroids (tested at 50% E/E0) include: 1 la-hydroxyprogesterone, 52-9%; 5ß-pregnane-3,20-dione, 36-3%; 5a-pregnane-3,20-dione, 4-7%; other C21 steroids <2%; Cortisol <0 1%; C19 and C18 steroids <0-l%.
Values for the intra-assay coefficient of variation, determined from repeated measurements of a high and low value marmoset plasma pool, were 5-3% at 23% E/E0 (mean value 46-9 ng/ml, = 40) and 8-1 % at 58% E/E0 ( ai, 1987) . The precision of the LH bioassay expressed as intra-and inter-assay coefficients ofvariation for replicate determinations ofa marmoset plasma pool was < 10% (n = 12) and < 15%(« = 6).
Results
The day of the luteal phase on which treatment was given was determined from the pattern of circulating progesterone concentrations (Day 1 of the luteal phase, i.e. one day after ovulation, was the day on which progesterone values rose above 10 ng/ml). Injection of vehicle on Day 10 or 11 of the luteal phase had no effect on the concentrations of progesterone or bioactive LH (Fig. 2) Harlow et al, 1983) . In contrast, the injection of 200 pg antagonist on Day 10 or 11 of the luteal phase caused a significant fall in plasma bioactive LH concentrations and a premature decline in luteal progesterone secretion. Mean + s.e.m. LH levels fell from 23-4 + 3-2 mi.u./ml immediately before injection to 3-4 + 0-6mi.u./ml 24h later (P < 001). Concentrations remained significantly lower than pre-injection values until the end of the period of measurement on Day 4.
In association with this decline in LH secretion there was a fall in progesterone concentrations from a mean ± s.e.m. value of 77-7 + 141 ng/ml on the day of antagonist injection to 3-6 + 0-5 ng/ml 1 day later (P < 0001). Progesterone concentrations remained below 10 ng/ml (range 1-2-4-2 ng/ml) from 2 to 13 days after antagonist, rising to a mean value of 11-1 +2-9 ng/ml on Day 15. In response to an injection of 100 pg antagonist on Day 10 or 11 of the luteal phase, LH concentrations fell from a mean + s.e.m. value of 14-4 + 1-3 to 4-7 + 0-8 mi.u./ml within 1 day of treatment. As with the 200 pg dose, mean LH concentrations 1, 2 and 4 days after injection were significantly lower than preinjection values (P < 001). Mean + s.e.m. progesterone concentrations declined significantly from 77-9 ± 24-3 to 5-2 + 1-7 ng/ml after 1 day, remaining low or undetectable until Day 13 when they rose to a mean value of 13-8 + 4-9 ng/ml.
Injection of 200 pg antagonist on Days 5 or 6 of the luteal phase also caused a fall in plasma bioactive LH concentrations and a premature decline in luteal progesterone secretion (Fig. 3) (Fig. 4) . LH concentrations remained low until Day 5 after which there was no significant difference from pre-injection values.
In intact animals the intervals from injection of antagonist to subsequent ovulation (i.e. day before the rise in plasma progesterone above 10 ng/ml) in the 3 treatment groups are shown in Table 1 . In control groups the mean interval from cloprostenol-induced luteal regression to ovu¬ lation was approximately 9-8 days, which agrees with previously published data for animals in our colony (Summers et al, 1985; Hodges et al, 1987) . Compared with this figure, the interval to ovulation was significantly lengthened in animals given 200 pg antagonist (early and mid-luteal phase) (P < 001) but not in animals given the 100 pg dose. Moreover, there was no overlap in the range of values for control and antagonist-treated cycles (200 pg dose). Luteal function in the cycle after antagonist injection appeared normal as judged by the maximum concentrations of circulating progesterone attained (not shown) and by the length of time for which progesterone concentrations exceeded 10 ng/ml (i.e. length of the luteal phase). The mean lengths of the luteal phase in the 3 treatment groups (range 19-3-21 days) were therefore not significantly different from those in animals receiving vehicle alone (21-3 ± 1-8 days) or from those previously reported for animals in this colony (19-2 + 0-6 days; Harlow et al, 1983) . A complete profile of progesterone concentrations during cloprostenol treatment, GnRH antagonist treatment (200 pg) and post-treatment cycles in an individual animal is shown in Fig. 5 . Values are mean ± s.e.m. and range.
tDays from injection of cloprostenol or GnRH antagonist to the day before the rise in circulating progesterone concentrations above 10 ng/ml. *Significantly different from previous cycle. (Asch et al, 1982; Balmaceda et al, 1983 ) the consensus from more recent studies, including the present one, is that continued pituitary luteotrophic support is essential (Hutchison & Zeleznik, 1984 Fraser et al, 1985 Fraser et al, , 1986 . Recent evidence also suggests that the relationship between corpus luteum function and pituitary LH varies with age, and that as the luteal phase progresses there is an increasing dependence upon luteotrophic support. Fraser et al. (1985 Fraser et al. ( , 1986 have reported that a single injection of GnRH antagonist into stumptailed macaques caused sustained suppression of progesterone secretion (i.e. luteal regression) when given during the mid-late luteal phase, whereas similar treatment during the early luteal phase (Day 7 or before) resulted in only temporary reduction in progesterone secretion and an apparent recovery of normal luteal function. In the marmoset, GnRH antagonist treatment was equally effective in inducing luteal regression when given during the early or midluteal phase. Whilst it is possible that species differences exist in the ability of the early corpus luteum to recover from acute LH deprivation, a more likely explanation for this difference is that the dose and/or potency of the antagonist used in the marmoset resulted in a more effective and/or sustained suppression of LH secretion than that achieved in the macaque studies. This is supported by the data from ovariectomized marmosets (Fig. 4 (Bramley et al, 1985) . The possibility of a direct action of the GnRH antagonist on primate ovarian cells therefore cannot be excluded. How¬ ever, in view of the suppression of LH secretion observed it is reasonable to assume that the GnRH antagonist-mediated effects on progesterone secretion in the present study were principally due to an action at the pituitary level.
In addition to the effects on corpus luteum function, treatment with the 200 pg dose of GnRH antagonist resulted in a prolongation of the subsequent follicular phase and a delay in the time to ovulation. Thus, the interval from GnRH antagonist-induced luteal regression to the rise in pro¬ gesterone concentrations above 10 ng/ml (i.e. day after ovulation) was on average 5 days longer than the comparable interval following induction of luteal regression with cloprostenol (Table 1 Delays in ovulation after temporary suppression of gonadotrophin secretion by GnRH antag¬ onists have also been reported for rhesus monkeys (Balmaceda et al, 1981; Borghi et al, 1983) and women (Mais et al, 1986) . In these studies, in which repeated daily injections of antagonist were given for 3-6 days from the beginning of the follicular phase, the delay in ovulation was generally equivalent to the duration for which the antagonist was administered. The results for the marmoset are therefore impressive in that a substantial delay in ovulation (up to Fig. 5 ). Similar findings of normal luteal function have also been reported for other primate species following the use of agonistic (Skarin et al, 1982; Borghi et al, 1983) and antagonistic (Asch et al, 1984; Mais et al, 1986) 
